Roche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion (€895 million).
Tag Archive for: licensing
Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the patient’s body.
GSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, triggering a $12 million (€11 million) milestone payment to the U.S.-based biotech.
Sanofi will pay Regeneron Pharmaceuticals $1 billion upfront (€0.9 billion) to expand the alliance that led to the blockbuster Dupixent with four antibody candidates designed to work longer between doses.
AstraZeneca has agreed to invest $2 billion (€1.8 billion) in Summit Therapeutics and test its cancer drug ivonescimab alongside the British pharma’s antibody-drug conjugates.
Swiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate for substance use disorders that has completed studies needed before a Phase 1 trial. Indivior ended the collaboration as it reorganizes R&D ahead of its proposed merger with Supernus Pharmaceuticals.
Roche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer antibodies. Together, the agreements have a potential value of more than $3.47 billion (€3.05 billion). Roche is paying $125 million (€110 million) upfront.
Boehringer Ingelheim has expanded its partnership with Variant Bio into cardiovascular disease, adding potential payments exceeding $250 million (€219 million). The agreement builds on a kidney disease collaboration signed in January.
Boehringer Ingelheim has partnered with New York-based Envisagenics to hunt for new targets in hard-to-treat solid tumors, opening up more than $1 billion (€873 million) in potential payments.
Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma group’s core oncology platforms.